Active substances scheduled for authorisation in 2020

ECHA published the Biocidal Products Committee work programme for 2020, specifying substances with authorisation date expected to be published in 2020.

ECHA published the Biocidal Products Committee work programme for 2020. The programme specifies 16 existing active substances to be processed in 2020. This means that authorisation date for each substance will be made public soon. This also means we are approaching the date for submitting the dossier for the authorisation of the biocidal products that contain such substance.

Active substance	EC	CAS	PT
Chlorophene	204-385-8	120-32-1	2
Glyoxal	203-474-9	107-22-2	2, 3, 4
Peroxyoctanoic acid		33734-57-5	2, 3, 4
Carbon dioxide obtained from propane, butane or a mixture of the two by combustion			19
Active chlorine obtained from sodium chloride by electrolysis			1-5
Active chlorine released from hypochlorous acid			1-5
N-(3-aminopropyl)-N-dodecylpropane-1,3-diamine (diamine)	219-145-8	2372-82-9
S-[(6-chloro-2-oxoxazolo[4,5-b]pyridin-3(2H)-yl)methyl]-O,O-dimethyl thiophosphate (azamethyphos)	252-626-0	35575-96-3	18
Ethylene oxide	200-849-9	75-21-8	2
Sulfur dioxide obtained from sulfur by combustion			4
Sulfur dioxide released from sodium metabisulfite			9
Alkyl (C 12-16 ) dimethylbenzyl ammonium chloride (ADBAC/BKC (C 12-16 ))	270-325-2	68424-85-1	3, 4
Didecyldimethylammonium chloride (DDAC (C 8-10 ))	270-331-5	68424-95-3	3, 4
D-Allethrin		231937-89-6	18
Esbiotrin		260359-57-7	18

ECHA published the Biocidal Products Committee work programme for 2020, specifying substances with authorisation date expected to be published in 2020.

Preparing a dossier for a biocidal product is a time-consuming and costly process. It is important to thoroughly investigate all options and prepare the best strategy before initiating the authorisation procedure for a biocidal product.

There are two strategies for how to stay in the game without having to cover all costs.

The first one is to avoid all unnecessary tests during the preparation of documentation for issuing authorisation for a biocidal product. Most people are scared off when they see that more than 100 tests need to be conducted in accordance with Annex II of the Biocidal Products Regulation. However, a good consultant is able to significantly lower the number of necessary tests using the existing data and eliminating unnecessary studies. So at the end fewer than 10 studies might be necessary.

What is more, if you have several similar biocidal products, you can notify them as a family of biocidal products. Instead of paying separately for studies for each product, you can pay for a single study for all products of the family.

Another strategy is to join forces with others. Minor companies will the lose battle against major ones if they do not join forces. The best way to reduce costs is to collaborate with someone with similar interests. As previously mentioned, authorisation can be issued for a family of similar biocidal products, and even if their composition and uses are not identical, you can still gain a lot from a joint authorisation.

We believe that it is extremely important that our clients understand the authorisation procedure. In this way, we can understand each other better and work together towards the same goal. And the goal is biocidal product authorisation at the lowest price possible.